Sanofi Consumer Healthcare India Ltd (NSE: SANOFICONR) and Strides Pharma Science Limited (Star) (NSE: STAR) are both listed in the Pharmaceuticals industry. Sanofi Consumer Healthcare India has a market capitalisation of ₹8,107 Cr and Strides Pharma Science ₹9,557 Cr, as of 9 Nov 2026. Their P/E ratios are 33.8 and 17.2 respectively. Return on equity is 73.09% for Sanofi Consumer Healthcare India and 20.03% for Strides Pharma Science. Over one year, Sanofi Consumer Healthcare India's share price is down 28.0% and Strides Pharma Science's is up 1.6%.
| Metric | Sanofi Consumer Healthcare India | Strides Pharma Science |
|---|---|---|
| NSE Symbol | SANOFICONR | STAR |
| BSE Code | 544250 | 532531 |
| Share Price | ₹3,445.00 | ₹1,000.10 |
| Market Cap | ₹8,107 Cr | ₹9,557 Cr |
| P/E Ratio | 33.8 | 17.2 |
| Return on Equity | 73.09% | 20.03% |
| Return on Assets | 37.99% | 6.26% |
| Dividend Yield | 2.13% | 0.48% |
| Beta (1Y) | 0.27 | 0.36 |
| 1-Year Price Change | -28.0% | +1.6% |
| 3-Month Price Change | -23.5% | +0.1% |
| 52-Week Range | ₹3,168.20 – ₹5,255.00 | ₹768.65 – ₹1,260.90 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹263 Cr | ₹1,430 Cr |
| Quarterly Net Profit | ₹77 Cr | ₹134 Cr |
| Net Margin | 29.1% | 9.4% |
| EPS (Basic, Quarter) | ₹33.26 | ₹14.19 |
| Results Basis | standalone | consolidated |
| Headquarters | Mumbai, Maharashtra | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited is a subsidiary of Opella Healthcare Participations B.V.
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer …
Strides Pharma Science has a market capitalisation of ₹9,557 Cr, against ₹8,107 Cr for Sanofi Consumer Healthcare India as of 9 Nov 2026, about 1.2 times the size by market cap.
Sanofi Consumer Healthcare India has a P/E of 33.8 and Strides Pharma Science a P/E of 17.2 as of 9 Nov 2026.
Sanofi Consumer Healthcare India has a return on equity of 73.09% and Strides Pharma Science 20.03%.
Sanofi Consumer Healthcare India's share price is down 28.0% over one year and Strides Pharma Science's is up 1.6%.
Sanofi Consumer Healthcare India reported revenue of ₹263 Cr and net profit of ₹77 Cr for Q2 FY27. Strides Pharma Science reported revenue of ₹1,430 Cr and net profit of ₹134 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.